• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
JNCE

JNCE

Jounce Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD1.88

+0.00 (+0.00%)

Company Profile

CEO

Kimberlee Cobleigh Drapkin CPA

IPO Date

2017-01-26

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$1.92

Prev. Close

$1.88

Day Low

$1.88

Day High

$1.93

52W Low

$0.58

52W High

$5.37

Market Cap

$0.10B

Volume

11.60M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

27.4%

Avg Negative

3.6%

Avg Neutral

69.1%

News Feed

Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Conference Call on Thursday, August 5, 2021

GlobeNewsWire·7/29/2021·↑ positive

Jounce Therapeutics: An Under The Radar And Undervalued Biotech

Seeking Alpha·7/13/2021·↑ positive

Jounce Therapeutics to Participate in William Blair's Biotech Focus Conference

GlobeNewsWire
·7/7/2021
·↑ positive

Why Jounce Therapeutics Bounced Higher Today

The Motley Fool·6/15/2021·↑ positive

Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/4/2021·↓ negative

Jounce Therapeutics, Inc. (JNCE) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research·5/4/2021·↑ positive

Jounce Therapeutics Reports First Quarter 2021 Financial Results

GlobeNewsWire·5/4/2021·↑ positive

Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

GlobeNewsWire·4/28/2021·↑ positive

Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting

GlobeNewsWire·4/10/2021·↑ positive

Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

GlobeNewsWire·3/12/2021·↓ negative